| 
 | Compound Information | SONAR Target prediction |  | Name: | CYCLOSPORINE |  | Unique Identifier: | SPE01502202 |  | MolClass: | Checkout models in ver1.5 and ver1.0 |  | Molecular Formula: | C62H111N11O12 |  | Molecular Weight: | 1090.73 g/mol |  | X log p: | 4.12  (online calculus) |  | Lipinksi Failures | 3 |  | TPSA |  |  | Hydrogen Bond Donor Count: | 5 |  | Hydrogen Bond Acceptors Count: | 12 |  | Rotatable Bond Count: | 12 |  | Canonical Smiles: | CC=CCC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C( =O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)
 C)C(=O)N(C)C(C(C)C)C(=O)N1(C)
 |  | Class: | macrolide |  | Source: | Tolypocladium inflatum |  | Reference: | Helv Chim Acta 60: 1568 (1977) |  | Therapeutics: | immunosuppressant |  | Generic_name: | Cyclosporine |  | Chemical_iupac_name: | Cyclosporine |  | Drug_type: | Approved Drug |  | Pharmgkb_id: | PA449167 |  | Drugbank_id: | BIOD00003 |  | Logp: | 4.293 |  | Cas_registry_number: | 59865-13-3 |  | Drug_category: | Immunmodulatory Agents; Immunosupressants |  | Indication: | For treatment of transplant rejection, rheumatoid arthritis, severe psoriasis |  | Pharmacology: | Used in immunosuppression for prophylactic treatment of organ transplants, cyclosporine exerts specific and reversible inhibition of immunocompetent
 lymphocytes in the G0-or G1-phase of the cell cycle. T-lymphocytes are
 preferentially inhibited. The T1-helper cell is the main target, although the
 T1-suppressor cell may also be suppressed. Sandimmune (cyclosporine) also inhibits
 lymphokine production and release including interleukin-2.
 |  | Mechanism_of_action: | Cyclosporine binds to cyclophillin. The complex then inhibits calcineurin which is normally responsible for activating transcription of interleukin 2. Cyclosporine
 also inhibits lymphokine production and ineterluekin relase.
 |  | Organisms_affected: | Humans and other mammals | 
 
 
	
		| Species: | 4932 |  
		| Condition: | SPE01500325 |  
		| Replicates: | 2 |  
		| Raw OD Value: r im | 0.3618±0 |  
		| Normalized OD Score: sc h | 0.5397±0 |  
		| Z-Score: | -13.8707±0 |  
		| p-Value: | 9.52883e-44 |  
		| Z-Factor: | 0.812153 |  
		| Fitness Defect: | 99.0594 |  
		| Bioactivity Statement: | Active |  | | Experimental Conditions |  |  | Library: | SpectrumTMP |  | Plate Number and Position: | 2|H8 |  | Drug Concentration: | 50.00 nM |  | OD Absorbance: | 0 nm |  | Robot Temperature: | 0.00 Celcius |  | Date: | 2006-08-13 YYYY-MM-DD |  | Plate CH Control (+): | 0.0397±0.00444 |  | Plate DMSO Control (-): | 0.67035±0.01920 |  | Plate Z-Factor: | 0.8868 | 
 |  png ps
 pdf
 | 
 
 
	
		| 6476563 | (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12 ,15,19,25,28-nonamethyl-3,6,9,18,24-pentakis(2-methylpropyl)-21-propan-2-yl-1,4,7,10,13,16,19,22,25,28,3
 1-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
 |  
		| 6476564 | (3R,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12 ,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28
 ,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
 |  
		| 6603775 | (3S,6S,9S,12S,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1S,2S)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12 ,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28
 ,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
 |  
		| 6604816 | (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12 ,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28
 ,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
 |  
		| 6610296 | (12R)-30-ethyl-33-[(1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-t etrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5
 ,8,11,14,17,20,23,26,29,32-undecone
 |  
		| 6711153 | (6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(1R,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12,15,1 9,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-dipropan-2-yl-1,4,7,10,13,16,19,22,25,28,31-u
 ndecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
 |  
 | internal high similarity DBLink  | Rows returned: 1 |  | 
 
 | active | Cluster 1190 | Additional Members: 4 | Rows returned: 0 |  | 
 
 |